Clinical characteristics of the KSHV− subgroup
| . | Post–severe acute respiratory syndrome coronavirus 2 vaccination (n = 13) . | Acute infection (n = 3): malaria (n = 1), HIV (n = 1), EBV (n = 1) . | Autoimmune disease (n = 2): IgG4-related disease (n = 1) and systemic lupus erythematosus (n = 1) . | Healthy donors (n = 3) . | P . |
|---|---|---|---|---|---|
| Sex, male, n (%) | 4 (31) | 3 (100) | 1 (50) | 2 (67) | .15 |
| Age, median (IQR), y | 36 (30-45) | 35 (33-41) | 58 | 30 (27-30) | .25 |
| . | Post–severe acute respiratory syndrome coronavirus 2 vaccination (n = 13) . | Acute infection (n = 3): malaria (n = 1), HIV (n = 1), EBV (n = 1) . | Autoimmune disease (n = 2): IgG4-related disease (n = 1) and systemic lupus erythematosus (n = 1) . | Healthy donors (n = 3) . | P . |
|---|---|---|---|---|---|
| Sex, male, n (%) | 4 (31) | 3 (100) | 1 (50) | 2 (67) | .15 |
| Age, median (IQR), y | 36 (30-45) | 35 (33-41) | 58 | 30 (27-30) | .25 |